ArticleScientific reports2026
MDM2 and DDIT3 coexpression in dedifferentiated liposarcoma with myxoid features: a retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dedifferentiated liposarcoma (DDLPS) can exhibit myxoid morphology that closely mimics myxoid liposarcoma (MLPS), creating significant diagnostic challenges. DDIT3 immunohistochemistry (IHC), a specific marker for MLPS, has been reported in a subset of DDLPS cases, but its frequency, staining pattern, and clinical significance remain poorly characterised. We retrospectively analysed 46 DDLPS cases with prominent myxoid features (≥ 10% myxoid component) confirmed by MDM2 IHC and fluorescence in situ hybridisation (FISH), treated at a single tertiary centre between January 2007 and January 2026. DDIT3 IHC was scored using a semiquantitative H-score system. DDIT3 positivity occurred in 11 of 46 cases (23.9%, 95% CI: 12.6-38.8%), predominantly as focal staining (9/11, 81.8%). All DDIT3-positive cases exhibited myxoid components comprising > 25% of tumour volume, versus variable myxoid extent in DDIT3-negative cases (p < 0.001). Mean H-score in DDIT3-positive cases was 48.6 ± 32.4 (range 15-120), significantly lower than in true MLPS controls (mean 278 ± 22, p < 0.001). Tumour size > 15 cm significantly increased the risk of local recurrence (risk ratio [RR] = 2.31, 95% CI: 1.02-5.24, p = 0.048). DDIT3 expression showed no significant association with local recurrence (p = 0.337), distant metastasis (p = 0.825), or mortality (p = 0.805). Kaplan-Meier analysis revealed no significant difference in overall survival (log-rank p = 0.782) or recurrence-free survival (log-rank p = 0.614) between DDIT3-positive and DDIT3-negative groups. DDIT3 positivity in DDLPS with myxoid features predominantly produces focal, low-intensity staining that distinguishes it from true MLPS. DDIT3 expression reflects chromosomal co-amplification within the 12q13-15 amplicon and lacks prognostic significance. Combined MDM2 and DDIT3 IHC with careful morphological assessment aids differential diagnosis, particularly when molecular testing is unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.